Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

Blood (2019) 134 (Supplement_1): 555.

https://doi.org/10.1182/blood-2019-130046

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Melissa Alsina, MD, Nina D. Shah, MD, David S. Siegel, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Jagoda K. Jasielec, MD, Yi Lin, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Timothy B. Campbell, MD PhD, Kristen Hege, Fabio Petrocca, MD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 927.

https://doi.org/10.1182/blood-2019-126660

Published: 2019

Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4085.

https://doi.org/10.1182/blood-2019-129347

Published: 2019

Journal Articles

LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial

Blood (2018) 132 (Supplement 1): 687.

https://doi.org/10.1182/blood-2018-99-119753

Published: 2018

Journal Articles

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Blood (2018) 132 (Supplement 1): 688.

https://doi.org/10.1182/blood-2018-99-110381

Published: 2018

Journal Articles

A Simplified Method for Transduction and Expansion of T Cells for Clinical Application

Mariam Khalil, Aaron Foster, PhD, Christine Gagliardi, PhD

Blood (2018) 132 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2018-99-119254

Published: 2018

Journal Articles

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

M. Judith Peterschmitt, MD, Selena Freisens, MD, Audrey W Hou, PharmD, Lisa Underhill, MS, Meredith C. Foster, ScD, Sebastiaan J.M. Gaemers, MD

Blood (2018) 132 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2018-99-118319

Published: 2018

Journal Articles

Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

Naveen Pemmaraju, MD, Bing Z Carter, PhD, Hagop M. Kantarjian, MD, Prithviraj Bose, MD, Tapan Kadia, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Naval Daver, MD, Zeev Estrov, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Lingsha Zhou, Po Yee Mak, Karina Salinas, RN, Carla Kay Tuttle, RN, Sherry Pierce, BSN, BA, Uday Popat, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 256.

https://doi.org/10.1182/blood.V130.Suppl_1.256.256

Published: 2017

Journal Articles

Eltrombopag (EPAG) Treatment Improved Platelet Counts in Patients with Persistent or Chronic Immune Thrombocytopenia during a 2-Year, Phase IV, Open-Label Study

Raymond SM Wong, MRCP,FRCP, Russell K Brynes, Attilio Orazi, Zeba Aziz, MD MBBS, Anait L. Melikyan, MD PhD, Abdulgabar Salama, Ozlem Ocak Arikan, Joan Maier, Tahir Shamsi, Professor of Haematology (FRCPath)

Blood (2017) 130 (Supplement 1): 3628.

https://doi.org/10.1182/blood.V130.Suppl_1.3628.3628

Published: 2017

Journal Articles

Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis

Ivo Veletic, MD, Taghi Manshouri, C. Cameron Yin, MD PhD, Kate J Newberry, PhD, Srdan Verstovsek, MD PhD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 1664.

https://doi.org/10.1182/blood.V130.Suppl_1.1664.1664

Published: 2017

Journal Articles

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Blood (2017) 130 (Supplement 1): 1631.

https://doi.org/10.1182/blood.V130.Suppl_1.1631.1631

Published: 2017

Journal Articles

Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)

Naveen Pemmaraju, MD, Bing Z Carter, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Courtney D DiNardo, MD, Prithviraj Bose, MD, Sherry Pierce, BSN, BA, Lingsha Zhou, Zeev Estrov, MD, Carla Kay Tuttle, RN, Karina Salinas, RN, Po Yee Mak, MPhil, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 3105.

https://doi.org/10.1182/blood.V128.22.3105.3105

Published: 2016

Journal Articles

Genome-Wide RNA Tomography of the Hematopoietic Stem Cell Niche in Zebrafish Reveals Unexpected Functional Macrophage-Stem Cell Interactions

Elliott J Hagedorn, PhD, Julie R Perlin, PhD, Clara Mao, BS, Brian Li, BS, Christopher D'Amato, BS, Raquel Riquelme, BS, Samantha Collins, BS, Karo Holler, MS, Alexander van Oudenaarden, PhD, Jan Philipp Junker, PhD, Leonard I. Zon, MD

Blood (2016) 128 (22): 3882.

https://doi.org/10.1182/blood.V128.22.3882.3882

Published: 2016

Journal Articles

Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition

Vikram Mathews, MD DM, Anu Korula, MD DM, Uday Kulkarni, MD, Saravanan Ganesan, MSc, Sachin David, MSc, Ansu Abu Alex, MSc, Nisham PN, MD DM, Aby Abraham, MD DM, Alok Srivastava, Kavitha M Lakshmi, MSc, Poonkuzhali Balasubramanian, MSc PhD, Biju George, MD DM

Blood (2016) 128 (22): 446.

https://doi.org/10.1182/blood.V128.22.446.446

Published: 2016

Journal Articles

Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

Petra Langerbeins, MD, Jasmin Bahlo, Christina Rhein, Paula Cramer, MD, Anna-Maria Fink, MD, Natali Pflug, MD, Julia von Tresckow, MD, Stephan Stilgenbauer, MD, Karl-Anton Kreuzer, Michael J. Eckart, MD, Ursula Vehling-Kaiser, MD, Rudolf Schlag, MD, Christina Balser, MD, Lothar Müller, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Michael Hallek, MD

Blood (2015) 126 (23): 2934.

https://doi.org/10.1182/blood.V126.23.2934.2934

Published: 2015

Journal Articles

A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)

Srdan Verstovsek, MD, Moshe Talpaz, MD, Ellen Ritchie, MD, Martha Wadleigh, MD, Olatoyosi Odenike, MD, Catriona Jamieson, MD PhD, Brady Stein, MD, Tomonori Uno, PhD, Ruben A. Mesa

Blood (2015) 126 (23): 2800.

https://doi.org/10.1182/blood.V126.23.2800.2800

Published: 2015

Journal Articles

AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)

Barbara Kiesewetter, MD, Richard Greil, MD, Wolfgang Willenbacher, MD, Peter Neumeister, MD, Michael A. Fridrik, MD, Raderer Markus, MD

Blood (2015) 126 (23): 3973.

https://doi.org/10.1182/blood.V126.23.3973.3973

Published: 2015

Journal Articles

The F-BAR Protein PACSIN2 Regulates Platelet Intracellular Membrane Architecture and in Vivo Hemostatic Functions

Terese Jönsson, Fred G Pluthero, Antonija Jurak Begonja, Jan Kormann, Mélanie Demers, Denisa D Wagner, Markus Plomann, John H Hartwig, Walter H Kahr, Hervé Falet

Blood (2014) 124 (21): 4154.

https://doi.org/10.1182/blood.V124.21.4154.4154

Published: 2014

Journal Articles

A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) – AGMT_CMML 1

Sonja Burgstaller, MD, Richard Greil, MD, Reinhard Stauder, MD MSc, Sigrid Machherndl-Spandl, MD, Michael Pfeilstöcker, MD, Thomas Kuehr, MD, Alois Lang, MD, Beate Mayrbaeurl, MD, Andreas L. Petzer, MD, Peter Valent, MD, Josef Thaler, MD

Blood (2014) 124 (21): 3268.

https://doi.org/10.1182/blood.V124.21.3268.3268

Published: 2014

NARROW

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

A Simplified Method for Transduction and Expansion of T Cells for Clinical Application

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

Eltrombopag (EPAG) Treatment Improved Platelet Counts in Patients with Persistent or Chronic Immune Thrombocytopenia during a 2-Year, Phase IV, Open-Label Study

Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)

Genome-Wide RNA Tomography of the Hematopoietic Stem Cell Niche in Zebrafish Reveals Unexpected Functional Macrophage-Stem Cell Interactions

Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition

Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)

AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)

The F-BAR Protein PACSIN2 Regulates Platelet Intracellular Membrane Architecture and in Vivo Hemostatic Functions

A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) – AGMT_CMML 1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only